Alexion Pharmaceuticals to pay $21M to resolve FCPA case

Alexion

Alexion Pharmaceuticals will pay $21 million to resolve SEC charges that it violated the books and records and internal accounting controls provisions of the FCPA concerning bribes made by subsidiaries to foreign government officials.

THIS IS MEMBERS-ONLY CONTENT

SINGLE MEMBERSHIP                                             CORPORATE MEMBERSHIP

You are not logged in and do not have access to members-only content.

If you are already a registered user or a member, SIGN IN now.